新肾康宁胶囊治疗早期高血压肾病的临床疗效观察

Clinical efficacy of observation new Shenkangning capsule in the treatment of early stage hypertensive nephropathy

[目的]观察新肾康宁胶囊治疗早期高血压肾病的临床疗效。[方法]选取早期高血压肾损害患者60例,随机分为治疗组及对照组各30例,两组均予血管紧张素转换酶抑制剂(ACEI)/血管紧张素Ⅱ受体阻滞剂(ARB)或钙离子拮抗剂降压治疗,治疗组同时予新肾康宁胶囊,4粒/次,每日3次,1个月为1个疗程,3个疗程后观察中医症状积分及治疗前后尿微量白蛋白(mAlb)、血清胱抑素C(Cys-C)指标的变化,并进行统计学分析。[结果]治疗组在中医症状的改善、mAlb、Cys-C指标的变化均优于对照组(P<0.05)。[结论]联合应用新肾康宁胶囊能够改善早期高血压肾病患者的临床症状,降低mAlb、及Cys-C指标,可能与改善肾脏缺血、缺氧状态有关,从而减轻肾小球硬化,延缓高血压肾病。

[Objective] To observe the clinical effect of the new new Shenkangning capsule in the treatment of early hypertensive nephropathy.[Methods] The essential hypertension patients with early renal injury in 60 cases, using random parallel control principle, divided into treatment group and control group with 30 cases in each group, two groups were treated with ACEI/ARB or calcium antagonist antihypertensive therapy, the treatment group at the same time with the Corelle kidney capsule, 4 pills, 3 times daily for 1 months the 1 course of treatment, after 3 courses of induction and the total scores of symptoms before and after treatment of urinary albumin and serum cystatin C （Cys-C） index changes, and statistical analysis.[Results] The treatment group in improving traditional Chinese medicine symptoms, urinary albumin （mAlb）, serum Cys-C index changes were better than the control group （P〈0.05）.[Conclusion] The combination of new Shenkangning capsule can improve the clinical symptoms of early hypertensive nephropathy, reduce urinary albumin and serum cystatin index may be associated with improved renal ischemia, hypoxia, reduce glomerular sclerosis, delaying renal damage in patients with essential hypertension.